Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 3/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 3/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.34 |
| ▸ | HTR2A | P28223 | 3/20 | 0.31 |
| ▸ | HTR2C | P28335 | 3/20 | 0.31 |
| ▸ | HTR2B | P41595 | 3/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1764779 | 0.88 | KDM1A (0.39) | PNMTLOXL2KDM1AKDM1BDPP4 | |
| SCHEMBL16794042 | 0.82 | KDM1A (0.49) | PNMTLOXL2KDM1AKDM1BDPP4 | |
| SCHEMBL29976628 | 0.82 | KDM1A (0.49) | PNMTLOXL2KDM1AKDM1BDPP4 | |
| SCHEMBL626553 | 0.81 | PNMT (0.50) | PNMTDPP4TAAR1 | |
| SCHEMBL31346729 | 0.81 | LOXL2 (0.42) | LOXL2DPP4TAAR1HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL2549784 | 0.81 | KDM1A (0.47) | PNMTLOXL2KDM1AKDM1BDPP4 | |
| SCHEMBL30139656 | 0.80 | PNMT (0.41) | PNMTLOXL2KDM1AKDM1BDPP4 | |
| SCHEMBL5012299 | 0.77 | KDM1A (0.38) | KDM1AKDM1BDPP4 | |
| SCHEMBL10741517 | 0.77 | KDM1A (0.33) | KDM1AKDM1BDPP4 | |
| SCHEMBL620594 | 0.76 | DPP4 (0.46) | LOXL2DPP4TAAR1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3609868-B1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | RAQUALIA PHARMA INC (JP) | 2023-10-18 | — | — | EP | disclosed |
| US-20230149382-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ASAHI KASEI PHARMA CORPORATION (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230149382-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ASAHI KASEI PHARMA CORPORATION (JP) | 2023-05-18 | — | — | US | disclosed |
| US-11077100-B2 | Tetrahydroquinoline derivatives as P2X7 receptor antagonists | RAQUALIA PHARMA INC. (JP) | 2021-08-03 | — | — | US | disclosed |
| US-20210085667-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2021-03-25 | — | — | US | disclosed |
| US-20200405706-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2020-12-31 | — | — | US | disclosed |
| US-20160326086-A1 | 4-HYDROXYBUTYRIC ACID ANALOGS | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2016-11-10 | — | — | US | disclosed |
| EP-2504324-B1 | SULTAM DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2015-02-25 | — | — | EP | disclosed |
| US-8314250-B2 | Sultam derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-20 | — | — | US | disclosed |
| CN-102753538-A | Sultam derivatives | HOFFMANN LA ROCHE | 2012-10-24 | — | — | CN | disclosed |
| EP-2504324-A1 | SULTAM DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011064141-A1 | SULTAM DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-03 | — | — | WO | disclosed |
| US-20110124686-A1 | SULTAM DERIVATIVES | ANDERSON KEVIN W | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200405706-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX3, P2RX1 | PNMT 2406/4885LOXL2 3436/4885KDM1A 3116/4885 |
| US-11077100-B2 | Tetrahydroquinoline derivatives as P2X7 receptor antagonists | P2RX7, P2RX3, P2RX1 | PNMT 2406/4885LOXL2 3436/4885KDM1A 3116/4885 |
| US-20160326086-A1 | 4-HYDROXYBUTYRIC ACID ANALOGS | HCRTR2, HCRTR1, HTR2B | PNMT 910/4885LOXL2 2527/4885KDM1A 273/4885 |
| US-20230149382-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX3, P2RX1 | PNMT 2406/4885LOXL2 3436/4885KDM1A 3116/4885 |
| US-20210085667-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX3, P2RX1 | PNMT 2406/4885LOXL2 3436/4885KDM1A 3116/4885 |
| US-20110124686-A1 | SULTAM DERIVATIVES | SULT1A1, SULT2A1, SULT1E1 | PNMT 355/4885LOXL2 4252/4885KDM1A 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.